Hälsa & åldrande

Researchers have found that a laboratory technique called RT-QuIC can reliably detect misfolded proteins linked to Lewy body dementia, a neurodegenerative disease often misdiagnosed as Parkinson's or Alzheimer's. Earlier, more accurate diagnosis could enable faster treatment and help pharmaceutical companies develop targeted therapies for this understudied form of dementia.EN

Researchers created the first human cell model that accurately reproduces Parkinson's disease, revealing how the disease damages mitochondria at the molecular level. Two experimental peptides successfully reversed these changes in the model, offering a faster, more reliable way to test potential therapies—potentially accelerating drug development for a disease affecting 10 million people worldwide.EN

A study of 500,000 UK adults found that frail individuals face nearly four times the risk of developing multiple degenerative bone and joint conditions simultaneously. The finding suggests that measuring physical vulnerability in clinical settings could help healthcare systems identify and treat high-risk patients earlier, potentially reducing costly complications and disability.EN

A comprehensive analysis of 45 studies involving 2 million people finds significant safety risks associated with antipsychotic drugs commonly prescribed to dementia patients for behavioral problems. The findings could reshape clinical practice and reduce healthcare costs, as guidelines already recommend non-drug interventions first—yet these medications remain widely used despite documented harms.EN

A continuous medication infusion for advanced Parkinson's patients significantly reduced involuntary movement downtime in a 6-month real-world trial, offering an alternative to surgery. The findings could reshape treatment options for the estimated 1 million Americans with Parkinson's, affecting healthcare providers, insurers, and pharmaceutical investment decisions.EN

Researchers developed a deep learning system that can synthesize expensive tau-PET brain scans from cheaper MRI scans and blood biomarkers with 77-86% accuracy. The breakthrough could dramatically lower diagnostic costs and expand access to early Alzheimer's detection, potentially reshaping how memory clinics, biotech firms, and insurers approach disease screening.EN

A new JAMA Neurology paper challenges the scientific foundation underlying Alzheimer's research and drug development. The findings could reshape how billions in biotech investment and regulatory decisions are directed—or force a reckoning with how the field has pursued treatments for decades.EN

Researchers tracking early dementia patients found that three plasma biomarkers—tau, GFAP, and neurofilament—reliably predict how quickly cognitive decline will progress. The findings could transform diagnosis and treatment monitoring, giving pharmaceutical companies and healthcare systems a tool to identify patients who need intervention earliest and measure drug effectiveness in clinical trials.EN

A major Norwegian study reveals that Alzheimer's disease pathology is far more common than previously thought, affecting nearly two-thirds of those over 90 and one-quarter of cognitively healthy older adults. The findings, based on blood tests in 11,486 people, have significant implications for healthcare planning, pharmaceutical development, and how societies prepare for aging populations.EN

En blodtest för fosforylerat tau 217 kan identifiera hjärnskador från upprepade huvudtrauman — en upptäckt som öppnar vägen för tidig upptäckt av kronisk traumatisk encefalopati (CTE) utan att vänta på obduktion. Boston University CTE Center och Sahlgrenska University Hospital analyserade blodprover från 231 deltagare mellan 2016–2023, däribland 177 före detta amerikanska fotbollsspelare och 54 opåverkade män. Fotbollsspelarna hade högre basala p-tau217-värden (0,35 mot 0,27 pg/mL), och nivåerna steg signifikant över tid (P < 0,001). Resultatet är relevant för anhöriga och äldre som är oroliga för långtidseffekter av tidigare huvudskador eller sportkopplad exponering. Biomarkören kan framöver möjliggöra tidigare intervention och behandlingsplanering — än så länge är testet forskningsverktyg men kan påverka klinisk praktik inom fem till tio år.

**Undernärda hjärt-kärlrisker förknippade med demenskognition** Högt blodtryck och förhöjda blodsockervärden diagnosticeras långt senare än de uppstår — särskilt i afrikanska befolkningar — och denna fördröjning kan öka demenrisken märkbart. Forskare från Wake Forest University granskade nästan 7 000 vuxna från Nigeria, Kenya och USA för att kartlägga hur ofta dessa hjärt-kärlrisker missas trots uppmätta höga värden. I Kenya och Texas kopplades förhöjt blodsocker till försämrad minnes- och tankefunktion. I Texas visade både allvarligt högt blodtryck och diabetes tydliga samband med demensmarkörerna pTau217, pTau181 och NFL i blodet. Resultaten pekar på betydande diagnostiska luckor i befolkningsgrupper med högt demensrisk. För äldre bör regelbundna blodtrycks- och glukoskontroller med åtgärd inte skjutas upp — de kan fördröja kognitiv nedgång genom att tackla den underliggande kardiometabola vägen till demens.

**Nya riktmärken gör demensprovningen mer tillförlitlig** Läkare behöver veta när kognitiva förändringar hos demenspatient är verkliga förändringar eller bara mätfel. Svenska forskare från Karolinska Institutet har nu definierat exakt vilka MMSE-poängförändringar som betyder något för Lewy body-demens och frontotemporal demens — något som aldrig gjorts innan. Studien följde 1 158 svenska patienter från registret SveDem under ett år och validerade resultaten med 1 060 amerikanska patienter. För Lewy body-demens krävs minst 0,7 poängs förändring för att räknas som verklig förändring, medan frontotemporal demens behöver 3,8 poäng. En naturlig årlig kognitiv försämring motsvarar 5–7 poäng. Resultaten hjälper kliniker tolka provresultat rätt och förbättrar utformningen av framtida läkemedelsprövningar för dessa sällsynta demenserformer.

Swedish researchers have created a frailty score that patients can self-report, rather than requiring time-consuming clinical assessments. The tool predicts mortality risk after stroke and could reshape how hospitals monitor millions of survivors, cutting costs while improving care decisions.EN

A major new initiative aims to prevent cognitive decline by catching Alzheimer's disease in its earliest stages, before patients experience memory loss or confusion. The approach could reshape how millions of Americans age and reduce the enormous public health burden of dementia—a priority for healthcare systems, insurers, and policymakers nationwide.EN

A new analysis of 137 studies reveals that most patients fail to stick with prescribed oral nutritional supplements, but researchers use inconsistent language to track the problem. The confusion over terminology and intervention design could be costing the healthcare industry millions in wasted treatments and delayed patient recovery.EN

A Swedish study of 347 patients aged 70+ found that mild-to-moderate frailty did not worsen long-term quality of life or daily functioning one year after colon cancer surgery. The finding challenges assumptions that frail patients should be denied surgery, potentially expanding treatment options for a vulnerable population and reducing unnecessary care rationing.EN

Researchers found that a metabolic marker of insulin resistance strongly predicted brain damage in older adults, but the harm flowed almost entirely through hypertension. The finding suggests blood pressure control may be the critical intervention point for preventing cognitive decline in metabolically at-risk populations—reshaping how insurers and health systems prioritize prevention spending.EN

A randomized trial shows that mobile health apps paired with remote check-ins significantly boost physical fitness and quality of life in Parkinson's patients months after leaving rehabilitation. The finding suggests digital follow-up programs could reduce the costly cycle of repeated inpatient stays by keeping patients engaged with exercise and nutrition long-term.EN

Researchers have successfully adapted and tested a clinical frailty assessment for Greenland's healthcare system, achieving near-perfect reliability among raters. The tool could help hospitals and clinics prioritize limited resources for their rapidly aging population and improve care planning decisions across remote communities.EN

A major clinical trial questions whether ordering amyloid PET scans early in memory clinic visits actually changes patient outcomes or treatment decisions. The finding could reshape how doctors approach dementia diagnosis and reduce unnecessary imaging costs for healthcare systems.EN

A new twin study published in Science Advances found that nicotinamide riboside—a form of vitamin B3—improved muscle mitochondrial function and beneficial gut bacteria. The finding could open a new category of supplements targeting age-related muscle decline and metabolic health, markets already worth billions.EN

A new cross-national study confirms that dementia runs in families—people with a parent diagnosed with dementia face substantially elevated risk themselves. The finding could reshape screening protocols and insurance underwriting practices while highlighting the need for early intervention strategies among high-risk populations.EN

A comprehensive review identifies biological markers that distinguish people who maintain sharp minds into old age from those who experience cognitive decline. The findings suggest chronological age is a poor predictor of mental sharpness—and point to targetable mechanisms that could reshape aging interventions and long-term care strategies.EN

Researchers have validated a gene variant called ABI3 S209F that increases Alzheimer's disease risk through a distinct biological pathway from the well-known APOE ε4 variant. The finding could enable companies developing diagnostics and therapeutics to better stratify patients and design targeted treatments, while helping healthcare systems identify high-risk individuals before symptoms emerge.EN

Researchers have developed and validated the SONNET scale, a 12-item assessment tool that measures social connection among long-term care residents. The instrument—which can be completed by residents or staff—addresses a critical gap in how care facilities track isolation and loneliness, metrics increasingly tied to health outcomes, resident satisfaction, and regulatory compliance.EN